Global Leading Market Research Publisher QYResearch announces the release of its latest report "Prions Testings - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". In clinical neurology and veterinary public health, the detection of transmissible spongiform encephalopathies (TSEs) presents a unique diagnostic challenge. Unlike conventional infectious agents, prions lack nucleic acids and rely on misfolded protein detection, requiring specialized assays capable of identifying pathological isoforms (PrP^Sc) with high sensitivity and specificity. This report quantifies the market trajectory of prions testing—a suite of laboratory methods addressing these diagnostic complexities through immunoassays, molecular biology techniques, and emerging amplification platforms. The global market for Prions Testings was estimated to be worth US$ 1,712 million in 2025 and is projected to reach US$ 2,531 million, growing at a CAGR of 5.8% from 2026 to 2032. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6097680/prions-testings Defining the Technology: Detection of Misfolded Prion Proteins Prions testing refers to a group of laboratory methods and diagnostic assays designed to detect the presence, activity, or misfolding of prion proteins (PrP^Sc), which are the infectious agents responsible for transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt–Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle, scrapie in sheep, and chronic wasting disease (CWD) in deer and elk. These assays are critical for clinical diagnosis, post-mortem confirmation, blood and tissue screening, and surveillance programs aimed at monitoring and controlling TSE transmission across human and animal populations. Market Segmentation: Immunoassays, Molecular Biology, and Emerging Platforms The Prions Testings market is segmented by assay type into immunoassays, molecular biology techniques, and others. Immunoassays—including enzyme-linked immunosorbent assays (ELISA) and Western blotting—represent the largest revenue segment, serving as the established standard for post-mortem diagnosis and regulatory surveillance programs. These platforms offer robust performance, established regulatory acceptance, and well-characterized antibody reagents targeting prion protein epitopes. Molecular biology techniques—including real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA)—represent the fastest-growing segment. RT-QuIC has emerged as the preferred method for ante-mortem diagnosis of Creutzfeldt–Jakob disease (CJD), demonstrating superior sensitivity in cerebrospinal fluid (CSF) and olfactory mucosa samples compared to traditional immunoassays. This technology has transformed clinical neurology practice, enabling earlier and more accurate diagnosis of sporadic and variant CJD. The "others" category encompasses emerging technologies such as digital droplet PCR for prion-associated biomarker detection and mass spectrometry-based approaches for prion protein characterization. Application Landscape: Clinical Neurology, Laboratory Diagnosis, and Research From an application perspective, the market serves three primary domains. Clinical neurology represents the fastest-growing segment, driven by adoption of RT-QuIC for ante-mortem CJD diagnosis. Recent clinical guidelines from the European Centre for Disease Prevention and Control (ECDC) and the U.S. Centers for Disease Control and Prevention (CDC) have incorporated RT-QuIC as a diagnostic criterion for probable and definite CJD, accelerating clinical adoption across major neurological centers. Laboratory diagnosis—including post-mortem confirmation and blood/tissue screening—represents the largest revenue segment, driven by regulatory surveillance programs for BSE, scrapie, and CWD. These programs require high-throughput immunoassay platforms capable of processing thousands of samples annually, with established regulatory protocols and proficiency testing requirements. Research and translational research applications encompass basic prion biology studies, drug discovery, and development of next-generation diagnostic platforms. This segment has seen increased activity following recent advances in understanding prion-like propagation mechanisms in neurodegenerative diseases, including Alzheimer's and Parkinson's, which share seeding and aggregation characteristics with prion diseases. Competitive Landscape: Specialized Diagnostics Providers and Global Life Science Leaders The competitive landscape features a mix of specialized prion diagnostics companies and global life science tools providers. Bio-Rad dominates the regulatory surveillance segment with its established immunoassay platforms for BSE, scrapie, and CWD testing, maintaining significant market share through long-term government contracts and regulatory approvals. Prionics AG and Roboscreen GmbH command substantial share in the European veterinary surveillance market, offering specialized ELISA kits and rapid tests for TSE screening. Eurofins, Abbott, and Roche participate through broader infectious disease and neurological diagnostic portfolios, with Roche's RT-QuIC platform gaining traction in clinical neurology applications. Enfer Scientific and Bioneer maintain regional strongholds in veterinary diagnostics, with Enfer holding significant contracts for BSE surveillance in European and Asian markets. Industry Deep-Dive: Chronic Wasting Disease Surveillance and Clinical Adoption Drivers Over the past six months, the industry has witnessed accelerated market activity driven by two converging factors. First, the geographic expansion of chronic wasting disease (CWD) in North American deer and elk populations has intensified surveillance requirements. As of Q4 2025, CWD has been detected in 34 U.S. states and 4 Canadian provinces, with prevalence rates exceeding 30% in some endemic regions. State and provincial wildlife agencies have expanded testing programs, driving demand for cost-effective, high-throughput immunoassay platforms capable of processing hunter-submitted samples with rapid turnaround. A recent case study from the Wisconsin Department of Natural Resources revealed that implementation of automated ELISA platforms with barcode tracking reduced sample processing time by 58% while maintaining diagnostic sensitivity above 99.5%, enabling the agency to expand surveillance coverage to previously underserved regions. Second, clinical adoption of RT-QuIC for CJD diagnosis has accelerated following publication of large-scale validation studies. A 2025 meta-analysis encompassing 2,847 patients demonstrated RT-QuIC sensitivity of 92% and specificity of 99% for sporadic CJD diagnosis using CSF samples, significantly outperforming traditional markers including 14-3-3 protein and tau. This evidence has driven adoption across academic medical centers and commercial reference laboratories, with major diagnostic providers expanding RT-QuIC service offerings. Exclusive Insight: Divergence Between Regulatory Surveillance and Clinical Diagnostic Segments A distinct adoption pattern emerges when analyzing market dynamics across application segments. Regulatory surveillance programs—including BSE monitoring and CWD management—operate as centralized, government-funded systems characterized by long-term contracts, established testing protocols, and emphasis on cost-per-test efficiency. Providers serving this segment must demonstrate validated platforms with regulatory approvals (e.g., OIE reference status), high-throughput capacity, and reliable supply chain for sustained program operations. In contrast, clinical diagnostic applications—particularly CJD diagnosis—operate through decentralized, hospital-based and reference laboratory models characterized by case-by-case testing, emphasis on clinical sensitivity, and integration with broader neurological workups. Providers in this segment must demonstrate strong clinical evidence, regulatory clearances (e.g., FDA, CE-IVD), and technical support infrastructure for specialized laboratory settings. This divergence has strategic implications for market participants. Suppliers targeting surveillance programs must prioritize cost efficiency, high-throughput automation, and established regulatory relationships. Those focused on clinical diagnostics must invest in clinical validation studies, specialty sales channels, and integration with neurological diagnostic algorithms. Technical Barriers and Innovation Frontiers Despite technological advances, the industry faces persistent technical barriers. Distinguishing variant CJD from sporadic CJD remains challenging, with implications for blood safety and public health surveillance. Researchers are developing discriminatory assays targeting strain-specific prion conformations, with several platforms entering clinical evaluation. Another frontier is the development of blood-based prion detection methods. Current ante-mortem diagnosis relies on CSF or olfactory mucosa sampling, limiting screening applications. Novel amplification platforms with enhanced sensitivity are under development for blood-based detection, with early-stage studies demonstrating proof-of-concept for variant CJD screening applications. Future Outlook: Sustained Growth Through Surveillance Expansion and Clinical Integration Looking toward 2032, the market is poised for sustained growth at a 5.8% CAGR, reaching US$2.5 billion. Key catalysts include continued geographic expansion of CWD surveillance programs, increasing clinical adoption of RT-QuIC for CJD diagnosis, and potential emergence of blood-based screening platforms for variant CJD surveillance. Providers who can deliver validated, high-sensitivity platforms with regulatory approvals across multiple jurisdictions—and who demonstrate expertise in both surveillance program deployment and clinical diagnostic integration—will capture disproportionate market share in this specialized segment. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp